Vaccitech PLC
F:2AB
Vaccitech PLC
F:2AB
Price:
0.46
EUR
-0.43%
Market Closed
Market Cap:
€18m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Vaccitech PLC
F:2AB
|
UK |
|
B
|
Bitdeer Technologies Group
NASDAQ:BTDR
|
SG |
|
NWF Group PLC
LSE:NWF
|
UK |
|
Access-Power & Co Inc
OTC:ACCR
|
US |
|
S
|
Shandong Cynda Chemical Co Ltd
SSE:603086
|
CN |
|
Ascletis Pharma Inc
HKEX:1672
|
CN |
|
R
|
Royal Unibrew A/S
CSE:RBREW
|
DK |
|
W
|
Wolford AG
VSE:WOL
|
AT |
|
Pennant International Group PLC
LSE:PEN
|
UK |
|
Nexpoint Real Estate Finance Inc
NYSE:NREF
|
US |
|
Airbus SE
PAR:AIR
|
NL |
|
Coca-Cola Bottlers Japan Holdings Inc
TSE:2579
|
JP |
|
FormPipe Software AB
STO:FPIP
|
SE |
Multiples-Based Value
The Multiples-Based Value of one
2AB
stock under the Base Case scenario is
hidden
EUR.
Compared to the current market price of 0.46 EUR,
Vaccitech PLC
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
2AB Multiples-Based Value
LOCKED
Multiples Across Competitors
2AB Competitors Multiples
Vaccitech PLC Competitors
Vaccitech PLC Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| UK |
|
Vaccitech PLC
F:2AB
|
18.8m EUR | 0 | -0.3 | 0.8 | 0.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
370.2B USD | 6.2 | 90 | 14.9 | 20.7 | |
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
356.2B USD | 109.7 | -1 712.3 | 15 906.4 | -1 796.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188B USD | 5.1 | 24.4 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
166.6B USD | 5.8 | 19.9 | 12.4 | 15.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110B USD | 9.4 | 28.5 | 21.4 | 22.3 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78B USD | 5.5 | 17.6 | 13 | 14.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
69B AUD | 3.1 | 34.4 | 11.4 | 14.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
